FindMyKOL
Clinical trialNCT00187512RecruitingObservational

SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era

NCT00187512 is an observational study sponsored by University of California, San Francisco. As of 21 Nov 2026, it is recruiting participants. It studies HIV Infections. The registry lists an enrollment of 2,500 participants at 1 site in 1 country. The registry lists a start date of 31 Mar 2000 and a primary completion date of 31 Dec 2032. One of its registered investigators has a FindMyKOL profile.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00187512
FieldValue
Registry IDNCT00187512
StatusRecruiting
Study typeObservational study
Lead sponsorUniversity of California, San Francisco
Enrollment2,500
Registered sites1
Countries1
ConditionsHIV Infections
Start31 Mar 2000
Primary completion31 Dec 2032
Study completion31 Dec 2033
Last update posted8 Sept 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

SCOPE is an observational, prospective study of HIV-1 infected volunteers designed to provide a specimen bank of samples with carefully characterized clinical data. SCOPE specimens will be used to examine multiple questions involving virologic, immunologic, and host factors involved in HIV-1 infection, progression, non-progression, response to treatment, control of HIV-1 virus, and evolution of drug resistance.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

California, United States1 site, 1 recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCalifornia: 1 site, 1 recruitingCA1NevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT00187512

Each answer restates registry values shown on this page.

What is NCT00187512?

NCT00187512 is an observational study sponsored by University of California, San Francisco. It studies HIV Infections.

Is NCT00187512 recruiting?

As of 21 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.

Who leads NCT00187512?

The registry names Steven G. Deeks, M.D. (principal investigator, University of California, San Francisco) as the overall official.

Where does NCT00187512 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

When is NCT00187512 expected to complete?

The registry lists a primary completion date of 31 Dec 2032 and a study completion date of 31 Dec 2033. The sponsor last updated the record on 8 Sept 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.